Case Study Bayer Corporation V Union Of India 2014

Case Study Bayer Corporation V Union Of India 2014 Case study: bayer corporation v. union of india (2014) the bayer corporation v. union of india case emphasizes the legal framework for granting compulsory licenses under the indian patents act, 1970, particularly to ensure that essential medicines are accessible at affordable prices. Bayer corporation vs union of india is a landmark case concerning the application of compulsory license under section 84 of the india patent act, 1970. the case addresses the interplay between patent rights and public health in india.

Case Study Bayer Corporation V Union Of India 2014 The active pharmaceutical substance “sorafenib,” which is used to treat liver and kidney cancer, was patented in india by the bayer corporation, a german company (patent no. in 215758). Bayer corporation held an indian patent for the drug sorafenib tosylate, marketed as nexavar, used in the treatment of liver and kidney cancer. the drug was extremely expensive — around ₹2.8 lakhs (inr) per month — making it unaffordable for most indian patients. In this case the petitioner has led no evidence to show the reasons for not manufacturing the patented drug in india or that the patented drug was being worked in india by import and further that import was justified. Bayer corporation, the petitioner in the present case, a company based in usa, researched and developed a drug for treatment of patients suffering from diseases related to kidney cancer and liver cancer.

Case Study Bayer Corporation V Union Of India 2014 In this case the petitioner has led no evidence to show the reasons for not manufacturing the patented drug in india or that the patented drug was being worked in india by import and further that import was justified. Bayer corporation, the petitioner in the present case, a company based in usa, researched and developed a drug for treatment of patients suffering from diseases related to kidney cancer and liver cancer. In this case commentary, we will discuss the court’s decision on this matter and how it will be remarked as meaningful for the future of patent rights and public health. This case revolves around india’s first major compulsory licence granted to natco pharma for bayer’s patented cancer drug sorafenib tosylate (nexavar). bayer argued that the licence violated its patent rights, while natco contended that the drug was unaffordable and inadequately supplied in india. Bayer corp. vs. union of india case summary the supreme court upheld india's first compulsory license for bayer's anti cancer drug nexavar, dismissing bayer's petition against the intellectual property appellate board's decision. By understanding the nuances of patent rights and the legal framework surrounding compulsory licensing, we can better appreciate the significance of bayer corporation v. union of india and its implications for patent law, public health, and access to affordable medicines in india.

Case Study Bayer Corporation V Union Of India 2014 In this case commentary, we will discuss the court’s decision on this matter and how it will be remarked as meaningful for the future of patent rights and public health. This case revolves around india’s first major compulsory licence granted to natco pharma for bayer’s patented cancer drug sorafenib tosylate (nexavar). bayer argued that the licence violated its patent rights, while natco contended that the drug was unaffordable and inadequately supplied in india. Bayer corp. vs. union of india case summary the supreme court upheld india's first compulsory license for bayer's anti cancer drug nexavar, dismissing bayer's petition against the intellectual property appellate board's decision. By understanding the nuances of patent rights and the legal framework surrounding compulsory licensing, we can better appreciate the significance of bayer corporation v. union of india and its implications for patent law, public health, and access to affordable medicines in india.

Case Study Bayer Corporation V Union Of India 2014 Bayer corp. vs. union of india case summary the supreme court upheld india's first compulsory license for bayer's anti cancer drug nexavar, dismissing bayer's petition against the intellectual property appellate board's decision. By understanding the nuances of patent rights and the legal framework surrounding compulsory licensing, we can better appreciate the significance of bayer corporation v. union of india and its implications for patent law, public health, and access to affordable medicines in india.

Case Study Bayer Corporation V Union Of India 2014